Bubs Australia secures permanent FDA authorization for three infant formulas, expanding its long-term access to the US infant nutrition market.
Written By: Creola Gonsalves, MS Biotech
Reviewed By: Pharmacally Editorial Team
Bubs Australia has secured permanent US Food and Drug Administration (FDA) authorization for Bubs Goat, Bubs 365 Day Grass Fed and Bubs Essential, establishing a long-term regulatory pathway for the Australian manufacturer to supply the US infant formula market. The authorization confirms that the three products, their manufacturing systems and supporting scientific evidence meet US requirements for safety, nutritional adequacy and quality.
Permanent US Authorization
The decision places Bubs among a limited group of non-US manufacturers authorized to supply infant formula in the United States. The company said the authorization strengthens its branded portfolio and provides a foundation for further product development and expansion in the US market.
Bubs already has products in more than 10,000 stores nationwide. Permanent authorization gives the company a more durable regulatory position from which to expand its US retail presence and evaluate additional infant nutrition opportunities.
Three Products Covered
The authorization applies to Bubs Goat, Bubs 365 Day Grass Fed and Bubs Essential. Unlike a drug approval, the FDA action concerns compliance with the regulatory framework governing infant formula, including nutritional adequacy, product safety and manufacturing quality.
The milestone also creates potential for broader portfolio development. Bubs said it will evaluate participation in the US private-label infant nutrition segment, although any such expansion would require additional regulatory, technical and commercial milestones.
Manufacturing and Supply-Chain Validation
Bubs CEO Joe Coote said the authorization validates the company’s manufacturing capabilities, product quality and farm-to-formula supply chain. The company plans to use the regulatory milestone to strengthen retailer relationships and expand consumer reach in the US.
The significance extends beyond retail access. Permanent authorization provides an established regulatory pathway for continued supply and reduces the uncertainty associated with relying on temporary or limited market-access arrangements.
FDA Intensifies Infant Formula Surveillance
Separately, the broader US infant formula market has faced heightened regulatory scrutiny in 2026. In April, FDA reported results from its largest-ever examination of chemical contaminants in infant formula, covering 312 samples from 16 brands. Most samples had undetectable or very low contaminant levels, and FDA said the findings affirmed the safety of the US infant formula supply. The agency is continuing testing and follow-up monitoring, including work on contaminants such as arsenic, lead, cadmium, mercury, PFAS, pesticides and phthalates.
FDA has also continued investigating infant-formula contamination and microbiological safety events, including a 2026 multistate infant-botulism investigation involving powdered formula.
Together, they illustrate a US infant formula market where product availability is expanding while regulatory testing, surveillance and supply-chain scrutiny remain intensive.
Next US Milestones
Bubs plans to discuss its US growth strategy during an investor webinar on September 10. The company expects permanent FDA authorization to support further branded expansion and provide an opportunity to assess private-label manufacturing.
For Bubs, the immediate milestone is permanent access to one of the world’s largest infant formula markets. For the wider sector, the development comes alongside an increasingly data-driven FDA approach to infant formula safety, with continued testing and oversight running in parallel with efforts to maintain a reliable and diverse supply of formula products.
Reference
These developments represent the wider regulatory environment rather than an explanation for the Bubs authorization. Bubs Australia, 07 September 2026
About the Writer
Creola Gonsalves (Linkedin) is an M.S. Biotechnology postgraduate with a strong interest in clinical research, evidence interpretation, and healthcare writing, with a focus on translating life-science knowledge into meaningful real-world insights.
She is trained in Good Clinical Practice (GCP), clinical research principles, and critical interpretation of randomized clinical trials, with certifications from NIH and Stanford University.
Her research background in biotechnological applications and microbial research strengthens her ability to understand scientific evidence and develop clear, accurate, and research-driven healthcare content.